China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) announced positive Phase II/III trial results for its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), demonstrating a robust immune response against the Omicron BA.5 subvariant, the dominant strain globally.
Trial Design
The global, double-blind, randomized, controlled SPECTRA trial included two cohorts:
- Homologous Third Dose: 3,755 participants in Brazil, Colombia, and the Philippines.
- Prior Infection Cohort: 14,692 participants in Belgium, Brazil, Colombia, the Philippines, and South Africa.
Immune Response
- A third dose of SCB-2019 in previously vaccinated individuals induced a 12-fold increase in neutralizing antibodies against BA.5.
- In participants with prior SARS-CoV-2 infection, two doses of SCB-2019 administered three weeks apart showed a 61-fold increase in antibodies against BA.5.
- The vaccine also demonstrated a 37-fold boost against BA.2 and a 20-fold boost against BA.1.-Fineline Info & Tech
